CELG News and Press, Celgene Corporation From 06/17/20

Quick Take Greenwich LifeSciences ( GLSI ) has filed to raise $23.5 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing an immunotherapy designed to prevent the recurrence of breast cancer. GLSI is preparing to enter Phase 3 trials ...

Quick Take Legend Biotech ( LEGN ) intends to raise $350 million in an IPO of its ADSs representing ordinary shares, per an amended registration statement . The company is advancing a pipeline of treatments for diseases of the blood and for solid tumors. LEGN has produced impressive res...

Quick Take Legend Biotech Corp. ( LEGN ) has filed to raise $100 million in an IPO of its ADSs representing ordinary shares, according to an F-1 registration statement . Legend Biotech is spinning out from parent firm GenScript Biotech to pursue treatments in CAR T cell therapies for mult...

Quick Take ADC Therapeutics ( ADCT ) intends to raise $125 million from the sale of its common stock, per an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood cancers and solid tumors. ADCT is making a new attempt to go pu...

It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...

In this episode of Rule Breaker Investing , Motley Fool co-founder David Gardner and Motley Fool analysts Karl Thiel and Maria Gallagher review three Five-Stock Samplers. Learn about their businesses, why they went up or down, and what lessons you can take away from this review so that you ca...

Acceleron Pharma (NASDAQ: XLRN ) and collaboration partner Bristol-Myers Squibb (NYSE: BMY ) announce the FDA nod for Reblozyl (luspatercept-aamt) for the treatment of anemia in certain adult patients with very low-to-intermediate-risk myelodysplastic syndromes who have failed treatment wi...

Quick Take Keros Therapeutics ( KROS ) intends to raise $75 million from the sale of its common stock, per an amended S-1/A regulatory filing . The company is advancing a pipeline of drug treatment candidates for hematological and musculoskeletal diseases. KROS is entering Phase 2 trial...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Celgene's ( CELG ) Zeposia (ozanimod) for the treatment of adults with relapsing remitting multiple sclerosis with active disease. More news on: Celgene Corporation, Bristol-Myers ...

This article is first in a series that provides an ongoing analysis of the changes made to Wedgewood Partners’ 13F stock portfolio on a quarterly basis. It is based on David Rolfe’s regulatory 13F Form filed on 02/14/2020. The 13F portfolio value decreased ~13%, from $1.13B to ...